Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kara M. Schenk, Julie E. Stein, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I. Khushalani, Jason J. Luke, Patrick Alexander Ott, Jeffrey A. Sosman, Vikram Aggarwal, Megan Davis Schollenberger, William Howard Sharfman, Elad Sharon, Serena M. Bagnasco, Janis M. Taube, Suzanne Louise Topalian, Daniel C. Brennan, Evan J. Lipson
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Northwestern University, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Moffitt Cancer Center, Dana-Farber Cancer Institute, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Johns Hopkins Medicine, Johns Hopkins Hospital, National Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4286295102